Silverarc Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Silverarc Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,921	Closed	-$1.49M	–	97
2023 Q1	$1.49M	Sell	13,921 -36,079	-72%	-$4.15M	0.62%	49
2022 Q4	$5.5M	Buy	+50,000	New	+$3.24M	1.57%	24
2021 Q2	–	Sell	-15,000	Closed	-$274K	–	123
2021 Q1	$274K	Buy	+15,000	New	+$310K	0.15%	82

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Silverarc Capital Management's RXDX Position: Q2 2023 in Review

Silverarc Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 13,921 shares — an estimated $1.49M sold.

Silverarc Capital Management first reported a position in RXDX in Q1 2021 and held it in 3 quarters. The position peaked at $5.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Silverarc Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Silverarc Capital Management sold 13,921 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.49M.
Silverarc Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Silverarc Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $5.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.